News
In Price Negotiations, Medicare Should Reassess How It Determines A ‘Qualifying Single Source Drug’
Conflicting QSSD definitions from two federal agencies mean that CMS’ administrative authority on drug pricing and payment is not well aligned with FDA’s authority to regulate drug safety and efficacy.
When Congress adopted the Inflation Reduction Act (IRA) in 2022, creating the Medicare Drug Price Negotiation Program (MDPNP), the bill did ...
CMS proposed several changes for the third round of Medicare drug price negotiations, including the potential inclusion of some drugs under Medicare Part B, in a draft guidance published May 12. The ...
An executive order from President Trump aims to make deep cuts to prescription drug costs, putting GOP lawmakers who have ...
CMS said on Monday that it would announce a list of 15 drugs eligible for a third round of Medicare price negotiations by early February next year. For the first time, the list would include drugs ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback